FourThought Financial Partners Boosts Eli Lilly Stake

Institutional investor increased its position in pharmaceutical giant by 71.9% in Q3 2025

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

FourThought Financial Partners LLC, an institutional investor, grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 71.9% in the third quarter of 2025, according to the company's latest Form 13F filing with the Securities & Exchange Commission. The investor now owns 5,433 shares of the pharmaceutical company's stock worth $4,146,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for its innovative medicines and therapies. This increase in ownership by FourThought Financial Partners signals the institutional investor's confidence in Lilly's long-term growth prospects, which could be driven by the company's robust pipeline of new drug candidates.

The details

FourThought Financial Partners added 2,273 shares to its Eli Lilly position during the third quarter, bringing its total holdings to 5,433 shares. The investor's increased stake is likely due to Lilly's strong financial performance and pipeline progress, which have driven the stock's price higher in recent quarters.

  • FourThought Financial Partners filed its Q3 2025 13F report in early November 2025.

The players

FourThought Financial Partners LLC

An institutional investment firm that manages assets on behalf of clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

Eli Lilly's continued growth and innovation have attracted the attention of major institutional investors like FourThought Financial Partners, signaling the company's strong position in the pharmaceutical industry.